GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Veraxa Biotech AG Ordinary Shares VRXA · USD

US listing · 🇺🇸 United States

Compare

1.01

+6.32%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$28,783

FY2023FY2025

Net income

−$81.8m

FY2023FY2025

Free cash flow

−$12.7m

FY2023FY2025

Shareholders' equity

−$19.4m

FY2023FY2025

Income statement

Fiscal years

FY2025FY2024FY2023
Revenue$28,783——
Gross profit$18,996——
Research and development$12.6m$7.8m$5.2m
Operating income−$82.3m−$35.5m−$20.5m
Net income−$81.8m−$34.6m−$20.3m
Diluted earnings per share-0.58-0.24-0.14

Balance sheet

At each fiscal year end

FY2025FY2024FY2023
Total assets$99.3m$104.2m$113.0m
Total liabilities$118.7m$66.0m$45.2m
Shareholders' equity−$19.4m$38.2m$67.7m
Shares outstanding141m141m141m

Cash flow

Fiscal years

FY2025FY2024FY2023
Cash from operations−$12.2m−$9.5m−$8.9m
Capital spending−$537,144−$148,518−$285,428
Free cash flow−$12.7m−$9.6m−$9.2m

Financial ratios

Data as of 5 Nov 2026

FY2025FY2024FY2023
Gross margin66.0%——
Operating margin-286020.0%——
Net margin-284359.2%——
Return on equity422.5%-90.6%-30.0%
Return on assets-82.4%-33.2%-18.0%
Free cash flow yield-7.4%-5.7%—
Earnings growth136.8%70.0%—
Current ratio0.44x2.20x7.39x
Equity ratio-19.5%36.6%60.0%
Interest coverage-18863.47x-98809.12x-16197.45x
R&D as a share of sales43815.1%——
Buybacks as a share of market value0.0%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings-10.6-23.5

Market value over time

29 May 2026 to 4 Nov 2026, in USD

$1.36bn$134.3m

Share price return

Finished calendar years

20252024
Return5%1%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.